Please login to the form below

Amylyx’s Relyvrio receives FDA approval for ALS treatment

Relyvrio was shown to significantly slow physical decline in people living with ALS

The two phase 3 trials showed a meaningful reduction in itching

For pursuing the case, the former employee will receive about $250m

The combination therapy significantly improved progression-free and overall survival rates

Tezspire demonstrated reduced annualised rate of asthma exacerbations

An application will also be submitted to the European Medicines Agency to extend the marketing authorisation for this age group

The positive phase 3 trial results assessing the treatment were published in NEJM Evidence

Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

Brexit means pharma must review its intellectual property rights across Europe

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London
SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway
Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours

Results demonstrated an overall response rate of 44% across multiple tumour types
AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial
BeiGene’s Brukinsa gets green light from NICE as Waldenström’s macroglobulinemia treatment

The condition occurs in less than 2% of patients with non-Hodgkin lymphomas
bluebird bio’s Skysona approved by FDA to treat cerebral adrenoleukodystrophy

The gene therapy was shown to slow the progression of neurologic dysfunction
AstraZeneca/Sanofi’s Beyfortus receives CHMP recommendation for prevention of RSV disease in infants

Beyfortus reduced the incidence of medically attended lower respiratory tract infections caused by RSV
Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

EFPIA confirms first and second vice-presidents

Novo Nordisk CEO Lars Fruergaard Jørgensen appointed first vice-president and Servier president Olivier Laureau confirmed as second vice-president
EFPIA appoints Hubertus von Baumbach as president

Von Baumbach will serve as president of the EFPIA for the next two years
ABPI appoints industry veteran Richard Torbett as new chief executive

Torbett initially joined the pharma association in March 2016
Professor Carole Longson moves from NICE to the ABPI

She joins the UK pharma body as its chief scientific officer
MedTech Europe appoints new board of directors

Chair of the board Michelle Brennan is among those newly elected

Scientific Team Leader, Scientific Services, Medical Communicati...: Highly competitive salary

Commercial Director, Medical Education, UK six figure package: Six figure salary

Business Development Director, Medical Education - exciting new ...: Up to £120K base

Business Unit Director, Healthcare Communications agency, London...: circa £135K

Associate Vice President, Scientific Services, Medical Communica...: Highly competitive salary

Add my company

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Is communication failing us?: Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?: A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.: Here are 5 healthcare marketing blunders and how best to avoid them....

Email:
Password: